Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Less than half of those who tested positive for HIV in Pretoria were aware of their HIV status. As such they would not have ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

The NMAC recently toured Nashville's Fisk University and five other HBCUs to register students to vote and discuss HIV ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...